Blood Pressure Medicines, Patients with Hypertension and COVID-19

The novel coronavirus (SARS-CoV-2) causes the infectious disease COVID-19. Certain characteristics of people who develop severe COVID-19 have been identified, including hypertension (high blood pressure). Since the pandemic began, however, there has been debate about whether the reason for severe disease in these patients is hypertension itself or antihypertensive medicines [particularly ACE inhibitors and angiotensin receptor blockers (ARBs)]. This is because the coronavirus binds to the ACE2 receptor to enter cells, and these blood pressure medicines can indirectly increase ACE2 expression on cell surfaces.
It has been suggested that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) affect susceptibility to COVID-19. Observational studies so far have shown that using these medicines does not increase COVID-19 risk, but because they are observational, their scientific evidence cannot be described as strong. A larger international analysis by Daniel R Morales and colleagues was therefore published on 17 December in THE LANCER Digital Health. With this most comprehensive study to date on hypertension medicines and COVID-19, they aimed to determine whether ACEI or ARB use in patients with hypertension was associated with increased susceptibility to COVID-19.
Do Blood Pressure Medicines Affect COVID-19 Risk?
This international cohort analysis, conducted using an open-science method, used electronic health records from Spain and the United States. Data from 1 November 2019 to 31 January 2020 were analyzed. More than 1.3 million patients were included.
Patients Were Divided into Two Groups:
Target Group: Users of ACEIs and ARBs,
Control Comparison Group: Users of calcium channel blockers (CCBs) and thiazide or thiazide-like diuretics.
Users were separately identified as receiving monotherapy with these four drug classes or combination therapy with other antihypertensive medicines.
The Study Evaluated These 4 Outcomes:
- Having received a COVID-19 diagnosis;
- Hospitalization with COVID-19;
- Hospitalization with pneumonia and
- Hospitalization due to pneumonia, acute respiratory distress syndrome, acute kidney injury or sepsis (severe disease).
Findings
Of the 1,355,349 antihypertensive users included in the analyses:
- 363 thousand used ACEI or ARB monotherapy,
- 249 thousand used CCB or thiazide monotherapy,
- 712 thousand used ACEI or ARB combination therapy and
- 473 thousand used CCB or thiazide combination therapy.
As the study's most important result, no association was observed between use of any blood pressure medicine group and COVID-19 risk.
Conclusion
No clinically meaningful risk of a COVID-19 diagnosis or hospitalization-related outcomes was observed with ACEI or ARB use, suggesting that users should not stop or change their treatment to reduce their COVID-19 risk.
*
What Do Earlier Studies Say about Blood Pressure Medicines and COVID-19 Risk?
The first randomized study comparing continued versus discontinued ACEIs or ARBs receptors in patients with COVID-19 showed no difference in the main outcomes between the 2 approaches. Similar 30-day mortality rates of 2.8% and 2.7%, respectively, were observed in patients who continued these medicines and those who suspended ACE inhibitor / ARB therapy (hazard ratio 0.97). In other words, stopping these medicines did not reduce COVID-19 mortality in patients with hypertension.
Some animal studies suggest that ACEIs and ARBs increase ACE2 expression (its amount or expression on cell surfaces), while studies reporting the opposite also exist.
RELATED TOPICS
- Covid-19 Current Statistics for the World and Turkey
- Breaking News and Scientific Developments about Coronavirus
*
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.